May 7, 2010.
ERBI
(Cambridge, UK), a not-for-profit membership organization for international life science and healthcare companies, and the
London Biotechnology Network
(LBN), a business network for London-based life science organizations, are to merge. The combined group will operate under the ERBI name, until the launch of a new identity at the ERBI Annual Conference on 2nd June.
The new organization combines ERBI’s 350+ members with LBN’s network of over 400 organizations across a wide range of life science industry sectors. The merger will mean that members have access to a significantly larger pool of companies to support business-to-business interaction, as well as an expanded training programme focused on the needs of life science companies. ERBI’s Harriet Fear becomes CEO of the merged companies; LBN leader Tony Jones becomes Director, Business Development, and a member of the senior management team.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.